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CLINICAL SCENARIO: 
 
 Cerebral palsy (CP) is a disorder of movement, muscle tone or posture that is 
caused by injury or abnormal development in the immature brain, most often before 
birth (Mayo Clinic staff, 2011). In the United States 3.3 per 1000 8-year old children 
have cerebral palsy, the leading cause of motor impairments in children (CDC, 2011). 
Currently there are approximately 500,000 children in the United States who have 
cerebral palsy and an additional 10,000 children are born with cerebral palsy each 
year (My Child, 2011). There are three types of cerebral palsy: spastic, athetoid, and 
ataxic. Spastic cerebral palsy is the most common form, accounting for approximately 
70% of all cases (emedicine.com, 2011). Symptoms of spastic CP include muscle 
weakness, loss of movement, tight muscles, abnormal gait patterns, and joint 
contractures. Symptoms may affect one or both sides of the body (Medlineplus, 2011).  
 
 Current treatments for children with spastic cerebral palsy include occupational 
and physical therapy, speech and language therapy, serial casting, orthotic devices, 
oral medications, intrathecal baclofen and botulinum toxin injections. Beginning in the 
1990s, botulinum toxin injections (BTX-A) have been used to treat spastic muscles 
associated with cerebral palsy (NINDS, 2011). BTX-A injections chemically denervate 
spastic or hypertonic muscles by inhibiting acetylcholine release from the terminal 
junction resulting in a temporary reduction in tone (Wallen et al, 2007). Botox is a 
brand of botulinum toxin commonly used for injections. 
 
 This treatment is not FDA approved, and limited research has been completed 
on this treatment method, especially with children. According to Botox™ the safety of 
this treatment has not yet been established for the purpose of treating spasticity in 
pediatric patients (Allergan, 2011). It is still unclear how BTX-A injections influence 
body structures and neurological process in the long-term (Barrett, 2011). Are the 
long-term effects worth the short-term benefits? 
 
 
FOCUSED CLINICAL QUESTION: 
 
What are the long-term effects of Botox treatment on upper extremity in 
pediatric clients who have Cerebral Palsy? 
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SUMMARY of Search, ‘Best’ Evidence’ appraised, and Key Findings:  Five 
research articles related to Botulinum toxin injections treating spasticity in pediatric 
patients with cerebral palsy were analysed by this writer. 
• The study by Lowe, Novak and Cusick (2006) was deemed as the “best 
evidence” evaluated. 
 The randomized control trial examined the effects of BTX-A injections for 
the purpose of improving upper extremity functions associated with 
cerebral palsy spasticity in children. The secondary purpose of this study 
was to determine is BTX-A injections in conjunction with occupational 
therapy results in greater functional improvements compared to BTX-A 
treatment only.  
 The study included a large sample size (N=72) and participants were 
representative of the general population. All participants maintained 
participation in their previous standard treatment, as it is unethical to 
withhold all treatment from a participant for the sole purpose of research. 
 The study examined 4 treatment combinations (OT only, BTX-A only, OT + 
BTX-A, no-treatment) to determine the best possible combination of 
spasticity treatment for children with cerebral palsy. 
 The duration of the study was 6 months during which time all participants 
were assessed on multiple measures for the purpose of determining the 
duration and effectiveness of treatment. 
 Statistically significant findings in both primary outcome measures at 3 
months post baseline indicating benefits of BTX-A injections and 
occupational therapy compared to the control group. 
• Findings reported by Lowe, Novak, & Cusick, (2006) support the use of BTX-
A injections in conjunction with occupational therapy for improving upper 
extremity function of spastic limbs for up to 3 months. 
• Fattal-Valevski, Sagi, Domenievitz, (2011) found that muscle tone was 
significantly reduced following BTX-A injections for up to 7 months, allowing 
for better opportunities for occupational therapy to work on positioning.  
• A randomized control trial by Russo et al, (2007) found that BTX-A injections 
in addition to occupational therapy resulted in improvements in functional 
abilities related to tone for 3 months following injections. 
• A study by Satila et al (2006) found that individuals who received BTX-A 
injections experienced improvements in upper limb movement patterns 
related to decrease tone, but did not experience an increase in functional 
abilities following serial BTX-A injections. 
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CLINICAL BOTTOM LINE:     
Results from the reviewed research indicate short-term benefits of BTX-A injections 
in addition to occupational therapy for the purpose of decreasing spasticity and 
increasing function of the upper extremity in children with cerebral palsy. There is a 
limited amount of research on this topic, specifically examining longer-term effects of 
BTX-A injection treatments. All studies reviewed in this paper found that significant 
differences between groups disappeared after 6 months, suggesting that 
occupational therapy provides the same health benefits in the long-term without the 
use of BTX-A injections. No research was located examining effects of injections for 
a longer duration. This intervention method must be administered by a well trained 
physician, can be very expensive and the safety of this treatment has yet to be 
determined for its use with children.  
 
 
 
 
 
Limitation of this CAT: This critically appraised topic has not been peer-reviewed. 
The search was not exhaustive and was completed by a master of occupational 
therapy student. The author is not an expert in this area.  
 
SEARCH STRATEGY: 
 
Terms used to guide Search Strategy: 
 
· Patient/Client Group: Children with cerebral palsy (spastic) 
 
· Intervention (or Assessment): Botox injections, spasticity treatment 
 
· Comparison: N/A 
 
· Outcome(s): long-term effects 
 
 
Databases and 
sites searched Search Terms Limits used Relevant Articles Retrieved 
CINAHL 
September, 2011 
“Botox 
Treatment”; 
“Cerebral Palsy” 
N/A (2 results; 1 used) 
 Wallen, M., & O’Flaherty, S.J. 
(2007) Archives of Physical 
Medicine and Rehabilitation 
 “Botulinum Toxin”; 
“Cerebral Palsy”; 
“Upper Extremity” 
Linked to full text (7 results; 2 used) 
Satila, H., Kotamaki, A., 
Koivikko, A., & Autti-Ramo, I. 
(2006) Pediatric Rehabilitation 
 
Lowe, K., Novak, I., & Cusick, 
A. (2006) Developmental 
Medicine & Child Neurology 
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MEDLINE-OVID 
September 2011 
“Botulinum Toxin”; 
“Cerebral Palsy”; 
“Upper Extremity” 
English 
language; full 
text, 2005-2011 
(7 results; 0 used) 
 “Botulinum Toxin”; 
“Cerebral Palsy”; 
“Upper Extremity”; 
“Children” 
 
English 
language 
(47 results; 2 used) 
Many none-applicable 
 
Russo, R. N., Miller, M., 
Murchland, S., Flett, P., & 
Haan, E. (2007) Pediatrics 
 
Fattal-Valevski, A., & 
Domenievitz, D. (2011) 
Journal of Child Neurology 
OT Search 
September 2011 
“Botulinum Toxin”; 
“Cerebral Palsy”; 
“Children” 
N/A (5 results; 1 used) 
1 repeat 
Some none-applicable 
Web of Science 
September 2011 
“Botulinum Toxin”; 
“Cerebral Palsy”; 
“Children”; “Upper 
Extremity” 
English; 2004-
2011 
(11 results; 0 used) 
Many none-applicable 
 
 
 
 
 
 
 
INCLUSION and EXCLUSION CRITERIA  
 
· Inclusion:  
· Full-text 
· English 
· Published after 2005 
· Intervention included BTX-A injections for treating upper extremity spasticity 
· Population </= 18years old, with spasticity related to cerebral palsy 
 
· Exclusion:  
· Adult populations with cerebral palsy  
· Lower extremity BTX-A injection treatment for spasticity  
 
 
RESULTS OF SEARCH 
 
Table 1:  Summary of Study Designs of Articles retrieved. Five relevant studies were 
located and categorised as shown in Table 1 (based on Levels of Evidence, Centre for 
Evidence Based Medicine, 1998) 
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Study Design/ 
Methodology of Articles 
Retrieved 
 
Level Number Located Author (Year) 
Randomized Control Trial II 3 
Lowe, K., Novak, I., & Cusick, A., 
(2006) 
 
Russo, R. N., Crotty, M., Miller 
M., Murchlan, S., Flett, P., & 
Haan, E., (2007) 
 
Wallen, M., O’Flaherty, S., & 
Waugh, M, (2007); Lowe, K., 
Novak, I., & Cusick, A., (2006);  
Case control study 
 
III 1 
Satila, H., Kotamaki, A., Koivikko, 
M., & Autti-Ramo, I., (2006) 
Pre-Post study III 1 Fattal-Valevski, A., Sagi, L., & Domenievitz, D., (2011) 
 
 
 
 
 
BEST EVIDENCE 
 
The follow article is identified as “best evidence” examining the effects of botulinum 
toxin injections for treating spasticity related to cerebral palsy in children. 
 
Wallen, M., O’Flaherty, S., & Waugh, M. (2007). Functional outcomes of intramuscular 
botulinum toxin type a and occupational therapy in the upper limbs of children 
with cerebral palsy: a randomized controlled trial. Archives of Physical 
Medicine and Rehabilitation, 88, 1-10. doi: 10.1016/j.apmr.2006.10.017 
 
 Reasons for selecting this study were: 
· Randomized control trial 
· Large sample size 
· Multiple outcome measures were used to obtain a deeper understanding of 
treatment effects 
· Longer study duration; 6 month follow-up assessment 
· Used common occupational therapy assessments 
· Occupational therapy sessions occurred most frequently (weekly) 
· Examined multiple variations / combinations of treatment options 
 
 
SUMMARY OF BEST EVIDENCE 
 
Table 2: Description and appraisal of “Functional outcomes of intramuscular 
botulinum toxin type a and occupational therapy in the upper limb of children with 
cerebral palsy: a randomized control trial” by (Wallen, M., O’Flaherty, S., & Waugh, 
M.,2007) 
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Aim/Objective of the Study:  
To determine if BTX-A treatment is an effective method of improving individualized 
functional outcomes and to determine if BTX-A injections in addition to occupational 
therapy is more effective than BTX-A alone in children with spastic cerebral palsy 
(Wallen, O’Flaherty & Waugh, 2007).  
 
Study Design:  
This study is a randomized control trial (RCT). Possible study participants were 
identified through the Physical Disabilities Clinic. Participant recruitment occurred 
through various pediatric therapy networks in the Sydney, Australia area. Assessment 
of eligibility for possible participants was determined by a rehabilitation pediatrician 
and a research nurse. Data collection occurred between June of 2000 and May of 
2002. All children participated in assessments of both physiological and self-perceived 
measures.  
Participants were randomly placed into one of 4 groups (including a control group) 
by a third party who was separate from all stages of the recruitment and eligibility 
process. Occupational therapy intervention was administered by each child’s usual 
occupational therapist. Assessment measures were administered at baseline, 2 weeks 
post, 3 months post, and 6 months post baseline by a pediatric occupational therapist, 
rehabilitation pediatrician and a research nurse. The research occupational therapist 
was blinded to participant group allocation and was different from the therapists who 
were administering therapy services. Other research professionals were not blinded to 
group allocations.  
 
Setting:  
This study took place at the Children’s Hospital at Westmead, in Sydney Australia. 
 
Participants:  
Sample included 72 children (n=72) who had spastic cerebral palsy affecting one or 
both upper extremities and were receiving services from the Physical Disabilities Clinic  
at the Children’s Hospital. Participants were recruited by a rehabilitation pediatrician at 
the hospital. Eligibility for participation in this study included being 2-14 years of age, 
having a diagnosis of spastic cerebral palsy affecting one or both upper extremities, a 
Modified Ashworth Scale (MAS) of 2 or 3, family identified goals and had received 
spasticity management treatment for a minimum of 6 weeks prior to the start of the 
study. Children who had significant contractures, an absence of movement or 
fluctuating muscle tone were ineligible for this study.  
 
The mean age of participants was 5 years, 11 months. 64 percent of the study 
participants were male. Of the 72 participants, 28 had quadriparesis, 11 experienced 
tetraplegia and 33 had hemiparesis. 96% of the upper extremities that were studied 
were the participant’s non-dominant arm. Group assignment to one of the four 
research groups was randomly drawn by an independent party. There were no 
significant differences between groups at baseline. 
 
This study received approval by the Ethics Committee of The Children’s Hospital at 
Westmead. All families and caregivers of study participants provided written consent 
for study participation and publication. 
 
Drop-outs reported: 
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•8 participants withdrew from this study prior to data collection at baseline 
Reasons noted for withdrawal: accepted to another study focusing on BTX-A 
injections, not satisfied with group allocation and unable to attend occupational 
therapy sessions. 
 
Intervention Investigated: 
 
Control:  
Group 1: The control group received no research related care. This group continued 
with their pre-study therapy throughout the duration of the study. 
 
Experimental: 
Group 2: BTX-A injections only - Under local anaesthesia and nitrous oxide sedation,  
participants in this experimental group, received one set of BTX-A injections at 
baseline to identified muscles. This group continued with their pre-study therapy 
through out the duration of the 6-month study. 
 
Group 3: Occupational Therapy intervention only - Beginning one week following 
baseline, participants in this group received one hour occupational therapy sessions, 
once a week for 12 weeks. Occupational therapy interventions included stretching, 
casting, splinting, motor training, environmental modifications and goal specific activity 
practice. Therapy was administered by each child’s usual occupational therapist. 
Therapy was not standardized, but focused on goal attainment of the individual’s 
goals. This group also continued with their pre-study therapy routine through out the 
6-month study. 
 
Group 4: Occupational therapy plus BTX-A injections - Participants in this 
experimental group received both BTX-A injections at baseline under local 
anaesthesia following the same protocol as the BTX-A injection only group (see group 
2) and weekly occupational therapy sessions (see group 3). Participants in this group 
were instructed to continue with their pre-study occupational therapy sessions in 
addition to study related treatments.  
 
Outcome Measures: 
All outcome measures were administered by the three research professionals 
(research occupational therapist, rehabilitation pediatrician, and research nurse) 
involved in data collection for this study at the Children’s Hospital at Westmead.  
 
Primary Outcome Measures: 
•Functional performance and satisfaction assessments: 
 
•Canadian Occupational Performance Measure (COPM): This assessment is a 
semi-structured client or caregiver interview with a focus on the occupational 
performance areas of self-care, productive and leisure participation. This 
assessment also examines the client’s satisfaction with their occupational 
performance. Previous research determined an effect of 2 points on the 10 
point scale was significant (Wallen, O’Flaherty, & Waugh, 2007). 
 
•Goal Attainment Scale (GAS): This assessment involves establishing goals 
and specifying a range of outcomes or behaviors that would indicate progress 
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toward achieving these goals. Specific outcomes are placed on a five point 
continuum where each point describes the degree of achievement to the goal 
(Willer, B., & Miller, G., 1976). 
 
Secondary Outcome Measures: 
•Upper limb function, functional skills: specifically self-care and range of motion 
 
•Quality of Upper Extremity Skills Test (QUEST): This 36 item outcome 
measure is designed to evaluate movement patterns and hand function in 
children with cerebral palsy. It assesses dissociated movement, grasp, 
protective extension and weight bearing (DeMatteo et al., 1993). 
  
•Pediatric Evaluation of Disability Inventory (PEDI): This standardized, 
normative assessment is used to measure capability and performance in the 
occupational areas of self-care, mobility and social function for children 6 
months to 7-years of age (Pearson Education, 2011). 
 
•Tardieu scale: This is a rating scale of spasticity in which the evaluator moves 
the selected limb through the range of motion at various velocities to determine 
the amount of spasticity present (We Move, 2011). 
 Main Findings:  
Table 3. Mean change scores for each experimental group for COPM (Performance 
and satisfaction) at baseline, 3 months and 6 months. 
 
Control 
Group(a) BTX-A only(b) OT only(c) BTX-A + OT(d) p 
Performance 
Baseline 3.2 3.1 3.5 2.4 0.016 
3 months 1.2 2.3 2.1 2.9 0.002(a vs. d) 
6 months 1.7 2.7 2.7 3.4 0.098 
Satisfaction 
Baseline 4.0 3.9 3.6 3.1 0.419 
3 months 1.4 2.8 2.5. 3.5 0.005(a vs. d) 
6 months 2.1 2.7 3.3 3.6 0.287 
 
 
Table adapted from: Wallen, M., O’Flaherty, S., & Waugh, M. (2007). Functional outcomes of 
intramuscular botulinum toxin type a and occupational therapy in the upper limbs of children with 
cerebral palsy: a randomized controlled trial. Archives of Physical Medicine and Rehabilitation, 88, 1-
10. (Original table © 2007, Archives of Physical Medicine and Rehabilitation) 
 
Results from this Kruskal-Wallis analysis show that significant differences were found 
between the control group and the BTX-A plus OT group  in both performance and 
satisfaction scores at 3 months. No significant differences were found between any 
groups at 6 months post baseline. 
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Table 4. Mean for GAS T scores at 3 months and 6 months.  
 
Control group(a) BTX-A only(b) OT only(c) BTX-A + OT(d) p 
Goal Attainment Scale 
3 months 32.9 42.3 42.2 51.0 0.000 (a vs. d) 
6 months 40.6 52.5 51.4 51.7 0.054 
 
 
 
Table adapted from: Wallen, M., O’Flaherty, S., & Waugh, M. (2007). Functional outcomes of 
intramuscular botulinum toxin type a and occupational therapy in the upper limbs of children with 
cerebral palsy: a randomized controlled trial. Archives of Physical Medicine and Rehabilitation, 88, 1-
10. (Original table © 2007, Archives of Physical Medicine and Rehabilitation) 
 
Results from this Kruskal-Wallis analysis show that significant differences were found 
between the control group and the BTX-A plus OT group on the GAS at 3 months. No 
significant differences were found between any groups at 6 months post baseline. 
 
 
Original Authors’ Conclusions: 
The study showed that BTX-A injections in conjunction with occupational therapy 
resulted in clear and earlier functional gains in comparison to other experimental 
groups. The evidence provided by this research suggest that the greatest amount of 
functional improvement can be elicited by the involvement of occupational therapy in 
children’s treatment immediately following BTX-A injections.  “The combination of OT 
and BTX-A injections enhances the self-reported, individualized, functional outcomes 
of children with cerebral palsy” (p. 9) 
 
Critical Appraisal: The main limitation of this study concerning the research question 
of this paper is that this study did not directly examine the long-term effect of 
BTX-A injections. Based on the results of this study, it is implied that the 
beneficial effects of BTX-A injections last only a few months.  
 
Validity: 
The authors included relevant background literature supporting the clinical question. 
The study design was appropriate for addressing the question while maintaining 
proper ethical issues and allowed the researchers to compare the experimental group 
to both occupational therapy treatment and to no intervention. 
 
Sample: Study sample size was based on the standards set by a previous study from 
the Canadian Association of Occupational Therapists. It determined that each 
group required a sample size of 19 participants to determine an effect of 2 points 
on the COPM 10 point scale. The sample also included inclusions and exclusion 
criteria to determine study population. Drop outs were reported within the 
research.  
 
Potential Biases: 
•Sample/Selection Bias: All participants were volunteers of the study, referred to 
the study by the research personnel at the Children's Hospital. 
1
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•Intervention/Performance Bias: (a) Co-intervention was not prevented during this 
study. Participants were instructed to continue their pre-existing treatments 
throughout the study. Thus, participants in the non-occupational therapy 
experimental groups may have been receiving some amount of occupational 
therapy during the 6-month study period. (b) Participants received their 
research occupational therapy sessions from their usual occupational 
therapist resulting in a possible bias. Variation between therapists and 
treatment methods may influence results of the study. 
 
Outcome Measures: 
•Canadian Occupational Performance Measure has been shown to have test-
retest reliability of 0.89 for performance and 0.88 for satisfaction.  
•Client Goal Attainment Scale has shown to correlate significantly with most other 
measure of treatment outcome.  
 
PEDro score: 8/10 
Random, concealed allocation; blind therapists, blind assessors; baseline 
comparability; adequate follow-up; between-group comparison;  
 
Interpretation of Results: This study was well designed and conducted in a manner 
to effectively determine the effects of BTX-A injections in comparison and 
conjunction with occupational therapy. The results form this randomized single-
blind control trial provides evidence that BTX-A injections have significant 
benefits in treating upper extremity spasticity associated with cerebral palsy in 
children. This research further supports the results of the additional studies 
reviewed in this CAT. In addition to providing additional support for the other 
articles it expanded on them by broadening the comparison of treatment options. 
The other studies reviewed in this CAT examined the difference between 
occupational therapy only and BTX-A injections in conjunction to occupational 
therapy. This study included 4 experimental groups, allowing for a more specific 
comparison of treatment options. However, like the other studies in this paper, 
this study also failed to find long-term benefits of using BTX-A injections for 
treating cerebral palsy related spasticity. 
 
Summary/Conclusion: 
This specific article found that BTX-A injections in addition to occupational therapy  
produced the greatest functional gains at 3-months post injections in comparison to 
the other experimental groups. The results from this study support the use of BTX-A 
injections for the purpose of short-term functional gains. Longer-term studies should 
be conducted in the United States to determine the physiological impact of BTX-A 
injections on children. 
 
 
 
 
Table 5: Characteristics of included studies  
Study Intervention investigated 
Comparison 
intervention  Outcomes used Findings  
1
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Lowe, K., 
Novak, I., & 
Cusick, A., 
(2006). 
To determine if 
children receiving 
occupational 
therapy would 
experience 
functional benefits 
from a single BTX-
A injection 6 
months post 
injection. 
Occupational 
therapy only 
•Quality of 
Movement at 6 
months(Quality of 
Upper Extremity 
Skills Test) 
•Quality of 
Movement, 
function and 
spasticity at 1 and 3 
months(Canadian 
Occupational 
Performance 
Measure, Pediatric 
Evaluation of 
Disability 
Inventory, 
Family/therapist 
Goal Attainment 
Scale, Modified 
Ashworth Scale) 
•Children who 
received BTX-A 
injections showed 
self-perceived 
functional 
performance 
improvements at 1 
and 3 months.  
•At 6 months, there 
were no significant 
differences 
between groups. 
(intervention group 
and OT only group 
made equal 
functions gains 
(self-perceived and 
functional 
assessments).  
•Only short-term 
benefits associated 
with BTX-A 
injections. 
Russo, R. N., 
Crotty, M., 
Miller M., 
Murchlan, S., 
Flett, P., & 
Haan, E., 
(2007). 
To explore the 
effect of localized 
BTX-A injections in 
conjunction with 
occupational 
therapy to treat 
upper extremity 
spasticity associated 
with cerebral palsy 
Occupational 
therapy only 
treatment sessions 
•Body structures 
(Modified 
Ashworth Scale; 
Assessment of 
Motor and Process 
Skills) 
•Functional self-
report and activity 
participation (Goal 
Attainment Scale; 
Self-perception 
profile for children; 
social acceptance 
for young children) 
•Self-competence 
(Pediatric 
Evaluation of 
Disability 
Inventory: self-care 
domain) 
•Functional 
benefits obtained 
through BTX-A 
injections for up to 
3 months.  
•No differences 
between groups 
after 6 months.  
•All groups made 
equal gains in 6 
months. 
1
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Fattal-
Valevski, A., 
Sagi, L., & 
Domenievitz, 
D., (2011). 
To investigate 
(1)the duration of 
effectiveness of 
BTX-A injections 
for the purpose of 
improving upper 
extremity function 
of children with 
spastic cerebral 
palsy, (2) the 
correlation between 
the duration of 
BTX-A effects and 
the likelihood that 
the patient would 
have additional 
treatments 
N/A; All study 
participants 
received BTX-A 
injections at some 
time 
•Body structures 
and functions 
(Range of Motion; 
Modified Ashworth 
Scale; Manual 
Ability 
Classification 
System) 
•Personal 
functional goal 
attainment (Parent 
questionnaire) 
•Muscle tone is 
decreased after 
BTX-A injections 
with a longer than 
clinically proven 
duration of effects.  
•Individuals who 
experienced 
functional 
improvements were 
more likely to 
request additional 
treatment 
injections.  
Satila, H., 
Kotamaki, A., 
Koivikko, M., 
& Autti-Ramo, 
I., (2006). 
To assess the effects 
of single or serial 
BTX-A injection 
treatments for the 
purpose of 
improving upper 
extremity function 
related to spasticity 
over the course of 
two years. 
N/A; All study 
participants 
received BTX-A 
injections (ranging 
from 1 to 4 
injections) during 
the course of the 
study. 
•Upper limb 
movement patterns, 
fine motor and 
bimanual functions 
(1-grip strength, 2-
Upper Limb 
Physician’s Rating 
Scale, 3-Melborne 
Assessment) 
•Caregiver 
perception (4-
Pediatric evaluation 
of Disability 
Inventory: 
Caregiver 
assistance scale) 
•Self-care abilities 
(5-Modified Goal 
Attainment Scale, 
6-Pediatric 
evaluation of 
Disability 
Inventory: 
functional skill 
scale) 
•Reduction in 
muscle tone 
following BTX-A 
treatment that did 
not result in 
improved quality of 
bimanual, fine 
motor, or grip 
functions.  
•Spasticity returned 
in all children 
within 6 months of 
treatment.  
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IMPLICATIONS FOR PRACTICE, EDUCATION and FUTURE RESEARCH 
 
 This study, and the other studies reviewed in this CAT have found that 
beneficial spasticity-related effects of BTX-A last approximately 12 weeks. This 
treatment method must be administer by a well-trained physician and can be 
expensive depending on the setting thus limiting its access to many patients with 
cerebral palsy. In addition to its potentially limited access, its safety has not yet been 
determined for use with children. Thus, the potential harm is not yet known. Additional 
research is needed to determine the long-term effects of this treatment. 
BTX-A injections are used in the United States to treat cerebral palsy related 
spasticity in children. This type of injection cost approximately $500 dollars per 
injection and is not covered by all insurances. All research articles that have been 
discussed in this paper found that the benefits that were present 3 months following 
BTX-A injections disappeared after 6 months. Yet this method of treatment is 
commonly used to treat spasticity in children with cerebral palsy. As children mature 
through adolescence, the body demands that muscles increase in size to cope with 
the increased mechanical demand associated with an increase in body size and motor 
functions. Although beneficial in the short-term, the muscle weakening that occurs 
from BTX-A injections may therefore be detrimental in the longer-term (Barrett, 2011).   
BTX-A injections were found to be of greatest benefit when administered in 
addition to continuous occupational therapy. However, in all studies discussed, these 
benefits were only significantly greater at 3 months. 6 months following injections 
children who had been receiving occupational therapy only were showing the same 
functional gains as those children who had received therapy in addition to Botulinum 
Toxin injections. Thus in the long-term children do not experience any greater 
functional benefits from having chemical injections. Botulinum toxin type A is 
considered to be one of the most potent poisons, and its use has been associated 
with respiratory tract infection, bronchitis, pharyngitis, muscle weakness, urinary 
incontinence, falls, seizures, fever, and unspecified pain (Friedman & Goldman, 
2011). The safety, efficacy and dosage of botulinum toxins have not been established 
for the treatment of limb spasticity of cerebral palsy or for use in any condition in 
children (FDA, 2010). Medical professionals must provide adequate educational 
information to caregivers of children with cerebral palsy so they can make appropriate 
decisions about their child’s treatment. 
 If children can make significant functional gains without the use of toxic 
chemical injections, it stands to reason that until there is indisputable proof that this 
treatment is safe for children it should be prescribed with great caution in severe 
circumstances. From an occupational therapy perspective, in which progress and 
health are established through the doing of occupations, the use of BTX-A injections 
to improve function related to spasticity should be used with extreme caution. At this 
time, research shows that children can make the same gains by participating in client-
centered occupational therapy without the use of injections. 
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